Metsera: $215 Million (Series B) Raised To Develop Medicines For Obesity And Metabolic Diseases
By Amit Chowdhry ● Nov 22, 2024
Metsera - a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases - announced the closing of a $215 million Series B funding round to further advance its portfolio of highly differentiated, clinical-stage, Nutrient-Stimulated Hormone (NuSH) analog peptides. Wellington Management and Venrock Healthcare Capital Partners led the financing, with participation from new investors including Fidelity Management & Research Company, Janus Henderson Investors, funds and accounts advised by T. Rowe Price Associates and by T. Rowe Price Investment Management, Viking Global Investors, Deep Track Capital, and RA Capital Management. Existing Metsera investors participated, including ARCH Venture Partners, Alpha Wave Ventures, GV, SoftBank Vision Fund 2, Newpath Partners, SymBiosis, and other undisclosed investors. Metsera has raised over $500 million to date.